HC Wainwright reaffirmed their buy rating on shares of Ekso Bionics (NASDAQ:EKSO) in a report released on Friday, BenzingaRatingsTable reports. They currently have a $12.00 price objective on the stock, up from their previous price objective of $8.00.
EKSO has been the topic of a number of other research reports. ValuEngine upgraded Ekso Bionics from a hold rating to a buy rating in a research report on Thursday, April 2nd. Zacks Investment Research lowered Ekso Bionics from a buy rating to a hold rating in a research report on Thursday, June 18th. Aegis reduced their price target on Ekso Bionics from $15.00 to $13.00 and set a buy rating on the stock in a research report on Thursday, May 21st. Finally, Cantor Fitzgerald upped their price target on Ekso Bionics from $1.00 to $8.00 and gave the company an overweight rating in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $9.25.
Shares of EKSO stock opened at $7.11 on Friday. The firm has a market capitalization of $66.57 million, a P/E ratio of -4.34 and a beta of 2.02. Ekso Bionics has a twelve month low of $2.25 and a twelve month high of $19.95. The company has a quick ratio of 1.53, a current ratio of 1.86 and a debt-to-equity ratio of 0.11. The stock’s fifty day simple moving average is $4.01 and its 200 day simple moving average is $1.93.
Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.17. The business had revenue of $1.47 million for the quarter. Ekso Bionics had a negative return on equity of 210.43% and a negative net margin of 68.97%. As a group, equities research analysts expect that Ekso Bionics will post -1.98 EPS for the current fiscal year.
About Ekso Bionics
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America, Europe, the Middle East, and Africa. The company operates through EksoHealth and EksoWorks segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries and hemiplegia due to stroke.
Featured Article: Balanced Fund
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.